Abstract：
UNASSIGNED: The use of insulin pumps (continuous subcutaneous insulin infusion [CSII]) in individuals living with type 1 diabetes (T1D) improves disease control. However, adverse skin reactions may hamper compliance. We aimed to assess the relationship of insulin pumps, particularly that of infusion set therapy, used in children and adults with T1D and dermatitis including allergic contact dermatitis (ACD).
UNASSIGNED: A systematic search of PubMed, and EMBASE, of full-text studies reporting dermatitis in persons with diabetes using a CSII was conducted from 2020 to 2023. The Newcastle-Ottawa Scale was used to assess study quality. The inventory performed at the Department of Occupational and Environmental Dermatology, Malmö, Sweden (YMDA) was also performed highlighting the diagnostic process.
UNASSIGNED: Among the 391 screened abstracts, 21 studies fulfilled the inclusion criteria. Seven studies included data on children only, four studies were on adults, and nine studies reported data on both children and adults. Participants were exposed to a broad range of pumps. Dermatitis was rarely specified. Up to 60% of those referred to a university hospital due to skin reactions possibly related to insulin pumps had an ACD.
UNASSIGNED: The review and our findings indicate that there is not sufficient focus on contact allergy in the primary toxicological evaluations of substances used also for insulin pump therapy products and that possible adverse skin reactions are not correctly followed up in the clinical setting.
UNASSIGNED: A systematic search of PubMed, and EMBASE, of full-text studies reporting dermatitis in persons with diabetes using a CSII was conducted from 2020 to 2023. The Newcastle-Ottawa Scale was used to assess study quality. The inventory performed at the Department of Occupational and Environmental Dermatology, Malmö, Sweden (YMDA) was also performed highlighting the diagnostic process.
UNASSIGNED: Among the 391 screened abstracts, 21 studies fulfilled the inclusion criteria. Seven studies included data on children only, four studies were on adults, and nine studies reported data on both children and adults. Participants were exposed to a broad range of pumps. Dermatitis was rarely specified. Up to 60% of those referred to a university hospital due to skin reactions possibly related to insulin pumps had an ACD.
UNASSIGNED: The review and our findings indicate that there is not sufficient focus on contact allergy in the primary toxicological evaluations of substances used also for insulin pump therapy products and that possible adverse skin reactions are not correctly followed up in the clinical setting.
摘要：
■在1型糖尿病（T1D）患者中使用胰岛素泵（持续皮下胰岛素输注[CSII]）可以改善疾病控制。然而,不利的皮肤反应可能妨碍依从性。我们的目的是评估胰岛素泵的关系，特别是输液器治疗，用于患有T1D和皮炎的儿童和成人，包括过敏性接触性皮炎（ACD）。
■对PubMed的系统搜索，和EMBASE,报告使用CSII的糖尿病患者皮炎的全文研究从2020年至2023年进行。纽卡斯尔-渥太华量表用于评估研究质量。在职业和环境皮肤病学系进行的清单，马尔默,瑞典（YMDA）也进行了突出的诊断过程。
■在391份经过筛选的摘要中，21项研究符合纳入标准。七项研究仅包括儿童数据，四项研究是针对成年人的，九项研究报告了儿童和成人的数据。参与者暴露于广泛的泵。很少指定皮炎。由于可能与胰岛素泵有关的皮肤反应而转诊到大学医院的人中，多达60％患有ACD。
■该综述和我们的发现表明，在胰岛素泵治疗产品中使用的物质的主要毒理学评估中，没有充分关注接触过敏，并且可能的不良皮肤反应在临床环境中没有得到正确随访。
■对PubMed的系统搜索，和EMBASE,报告使用CSII的糖尿病患者皮炎的全文研究从2020年至2023年进行。纽卡斯尔-渥太华量表用于评估研究质量。在职业和环境皮肤病学系进行的清单，马尔默,瑞典（YMDA）也进行了突出的诊断过程。
■在391份经过筛选的摘要中，21项研究符合纳入标准。七项研究仅包括儿童数据，四项研究是针对成年人的，九项研究报告了儿童和成人的数据。参与者暴露于广泛的泵。很少指定皮炎。由于可能与胰岛素泵有关的皮肤反应而转诊到大学医院的人中，多达60％患有ACD。
■该综述和我们的发现表明，在胰岛素泵治疗产品中使用的物质的主要毒理学评估中，没有充分关注接触过敏，并且可能的不良皮肤反应在临床环境中没有得到正确随访。
